Savin Ziv, Herzberg Haim, Schreter Eran, Ben-David Reuben, Bar-Yosef Yuval, Sofer Mario, Beri Avi, Yossepowitch Ofer, Mano Roy
Department of Urology, Tel-Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Can Urol Assoc J. 2021 Sep;15(9):E465-E470. doi: 10.5489/cuaj.6907.
We aimed to compare the treatment patterns and oncological outcomes, including postoperative morbidity and chemotherapy use, between octogenarians and patients <80 years of age who underwent radical cystectomy for bladder cancer.
We conducted a retrospective analysis of 119 patients who underwent radical cystectomy for bladder cancer at our center between January 2013 and April 2019. Comorbidities, clinical and pathological data, 30-day postoperative morbidity, and perioperative chemotherapy use were compared between octogenarians (n=31) and younger patients (n=88). Cancer-specific and overall survival rates were estimated with the Kaplan-Meier method and compared between the groups.
No significant differences were found between the age groups in the clinical and pathological findings, including Charlson comorbidity index, modified frailty index, albumin level, renal function, and TNM stage. The median followup for survivors was 19 months (interquartile range [IQR] 11-30). Major complications (Clavien-Dindo grade ≥3) and 30-day postoperative mortality rates did not differ between the age groups (p=0.3 and p=0.18, respectively). Despite no difference in baseline glomerular filtration rates, perioperative chemotherapy utilization rate was lower among octogenarians compared to younger patients (13% vs. 34%, p=0.03). Estimated two-year cancer-specific survival rates for octo-generians and younger patients were 40% and 75%, respectively. Similarly, estimated two-year overall survival rates were 30% and 69%, respectively. Both cancer-specific and overall survival rates were significantly lower in octogenarians (p=0.007 and p=0.001, respectively).
Radical cystectomy in octogenarians results in comparable short-term outcomes as in younger patients. However, in the elderly population, perioperative chemotherapy utilization rates are lower and survival is inferior.
我们旨在比较八旬老人与80岁以下因膀胱癌接受根治性膀胱切除术的患者的治疗模式和肿瘤学结局,包括术后发病率和化疗使用情况。
我们对2013年1月至2019年4月期间在本中心因膀胱癌接受根治性膀胱切除术的119例患者进行了回顾性分析。比较了八旬老人(n = 31)和年轻患者(n = 88)的合并症、临床和病理数据、术后30天发病率以及围手术期化疗使用情况。采用Kaplan-Meier方法估计癌症特异性生存率和总生存率,并在组间进行比较。
各年龄组在临床和病理结果方面无显著差异,包括Charlson合并症指数、改良虚弱指数、白蛋白水平、肾功能和TNM分期。幸存者的中位随访时间为19个月(四分位间距[IQR] 11 - 30)。各年龄组的主要并发症(Clavien-Dindo分级≥3)和术后30天死亡率无差异(分别为p = 0.3和p = 0.18)。尽管基线肾小球滤过率无差异,但八旬老人围手术期化疗使用率低于年轻患者(13%对34%,p = 0.03)。八旬老人和年轻患者的估计两年癌症特异性生存率分别为40%和75%。同样,估计两年总生存率分别为30%和69%。八旬老人的癌症特异性生存率和总生存率均显著较低(分别为p = 0.007和p = 0.001)。
八旬老人行根治性膀胱切除术的短期结局与年轻患者相当。然而,在老年人群中,围手术期化疗使用率较低且生存率较差。